- Patient apheresis heterogeneity from prior systemic therapy, collection settings, anticoagulants, timing, and transport/cryopreservation cannot be “standardized away” and materially impacts identity, potency, and yields.
- Inadequate inclusion of clinically representative starting material during development drives nonrobust parameters, higher GMP batch failure rates, and reactive redesign that delays programs and jeopardizes last-line treatment delivery.
- Read the full article here: PharmTech
The Medicine Maker 2026 Power List
Celebrating 60 inspirational individuals – across small molecules, biopharma, and cell and gene therapy – who are helping to translate pharma’s...